# Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function

> **NCT02340195** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 16 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Idalopirdine (Lu AE58054) 60 mg

## Key facts

- **NCT ID:** NCT02340195
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-09
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02340195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02340195, "Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02340195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*